CClinicalTrials.gg
CompletedNCT05845957Updated May 6, 2023

Digital Storytelling in Pediatric Safe Drug

An interventional study of Digital Education Group in Education, Nursing and Innovativeness, sponsored by Ege University. Completed at 1 site in Turkey. Open to participants aged 19 Years to 23 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-05-06.

Sponsored by Ege University · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Registered 1 year 4 months after the study started (first participant enrolled Dec 2021, registered Apr 2023).
Phase
Not applicable
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
19 Years to 23 Years
Sex
All
01

Study summary

Summary Aim: This research was conducted to determine the effectiveness of education given to students using digital storytelling in safe pediatric intravenous drug administration.

Method: It is a randomized controlled experimental study. The sample of the study consisted of 84 nursing students. The students included in the study were divided into two equal groups: the experimental and control groups. Digital education material of the experimental group and theoretical education was applied to the control group. Before and after the training, a post-knowledge test was made and evaluated.

02

Conditions studied

  • Education
  • Nursing
  • Innovativeness

Keywords

  • Nursing students
  • Education
  • Digital stroytelling
  • pediatrics
  • safe drug application
03

In context

Lead sponsor

Ege University is the lead sponsor of 365 studies on the registry; 46 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 23 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Being a student of the Department of Nursing
  • Taking the child health and diseases nursing course and being successful
  • Volunteering to participate in the research

Exclusion criteria

Exclusion Criteria:

  • Participate and quit the study
  • Being a 1st and 2nd year nursing student
  • Failure of the child health and diseases nursing course
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
84 participants (actual)

Study arms

  • Experimental
    Digital Education Group

    All participants in this group were given the "Safe pediatric intravenous drug administration knowledge test" prepared by the researchers as a pre-test. The participants of this group, who were determined by randomization, were given training prepared using the digital storytelling method. The training took 25 minutes. After the training, the "Safe intravenous drug administration knowledge test" was applied as a post-test.

    Other: Digital Education Group

  • No intervention
    Control Group

    No intervention was made. All participants in this group were given the "Safe pediatric intravenous drug administration knowledge test" prepared by the researchers as a pre-test. Afterward, theoretical information on the subject was given. After theoretical information, the "Safe intravenous drug administration knowledge test" was applied as a post-test.

Interventions

  • OtherDigital Education Group

    Providing training on safe pediatric intravenous drug administration with digital storytelling method

06

What researchers measure

Primary outcomes

  1. Statistical difference between groups about knowledge test scores

    Safe pediatric drug practices knowledge test is applied twice as pre-test and post-test in experimental and control groups. Safe pediatric drug practices knowledge test: It is a 17-question form prepared by researchers. Content validity has been made for the form. Each correct answer is calculated as 1 point and each wrong answer is calculated as 0 points. The higher the score obtained from the questionnaire, the higher the level of knowledge.

    Time frame: During the education, approximately 25 minutes

07

Study locations

1 site
  • Semih
    İzmir, 35665, Turkey
08

References and documents

Individual participant data

Plan to share: No — The study will be prepared for publication

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05845957
Lead sponsor
Ege University
Collaborators
Izmir Bakircay University
Responsible party
Şeyda BİNAY YAZ (Assistant professor, Ege University) — Principal investigator
First posted
May 6, 2023
Start date
Dec 8, 2021
Primary completion
Apr 30, 2022
Completion
Apr 6, 2023
Last update
May 6, 2023

Study contacts

Semih Akkoyun
principal investigator · Izmir Bakircay University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion